Loading...
HIV-1 is genetically diverse, and although subtype B has predominated in Europe and North America, non-B strains constituted almost 90% of isolates worldwide between 2004 and 2007. The natural history and response to treatment of non–B subtype virus infection is not well characterized, and all previous studies have been conducted using patients with chronic infection. Now, to address these issues, researchers have analyzed data from two large cohort studies involving patients with known date of infection.
Chaix and colleagues compared response to combination antiretroviral therapy (ART) between 285 patients with non–B subtype infection and 843 patients with subtype B infection enrolled in a prospective French cohort of individuals with prima…